XOMA (NASDAQ:XOMA) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of XOMA (NASDAQ:XOMA) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $123.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a research note on Friday, December 27th.

XOMA Stock Performance

XOMA opened at $25.74 on Tuesday. The firm has a fifty day moving average price of $29.20 and a 200 day moving average price of $27.94. XOMA has a 1 year low of $18.57 and a 1 year high of $35.00. The stock has a market cap of $303.29 million, a P/E ratio of -7.40 and a beta of 0.92. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

Insider Activity

In related news, CEO Owen Hughes sold 21,881 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Several institutional investors have recently modified their holdings of XOMA. BNP Paribas Financial Markets raised its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the last quarter. Rhumbline Advisers increased its stake in XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares in the last quarter. Barclays PLC raised its holdings in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 8,447 shares during the last quarter. Ellsworth Advisors LLC purchased a new position in shares of XOMA in the third quarter valued at approximately $516,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after acquiring an additional 1,968 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.